Navigation Links
The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients
Date:5/22/2013

tients with such unmet medical needs, What makes this project even more exciting to support is that the technology was developed by Professor Sherie Morrison at UCLA while she was funded by a LLS Translational Research Grant.  LLS continues to find that funding through its research grant programs leads to discoveries that move on to biotechnology companies like Valor Biotherapeutics, LLC, who are more fully able to bring novel therapeutics to patients with blood cancer." 

Dr. Rahul Singhvi , chief executive officer of Valor Biotherapeutics, stated:  "We thank LLS for their commitment to our antibody-interferon fusion platform and their crucial financial support of the IGN002 program.  This funding represents a substantial investment in the development of IGN002 and will enable its development through Phase 1 clinical testing.  In addition, we welcome the opportunity to work with LLS and benefit from their vast experience in the lymphoma area as we advance IGN002 into clinical trials."

"IGN002 has demonstrated dramatic efficacy in rituximab-resistant preclinical models. The financial commitment by our JV partner, Caliber and the LLS will help in advancing this program to the proof-of-concept study in NHL patients.  Our R&D team is very excited to work with the LLS and Valor, to advance IGN002 to the clinic," said Sanjay D. Khare , Ph.D., president and CEO of ImmunGene, Inc. "This study will help us in understanding the utility of the technology for several other programs in the ImmunGene pipeline."

About The Leukemia & Lymphoma Society
The Leukemia & Lymphoma Society ® (LLS) is the world's largest voluntary health agency dedicated to blood cancer. The LLS mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. LLS fun
'/>"/>

SOURCE The Leukemia & Lymphoma Society
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Leading Leukemia Experts: High Leukemia Treatment Costs May Be Harming Patients
2. Tosedostat OPAL Study in Acute Myeloid Leukemia Published in Lancet Oncology
3. Launch Of Premium-priced, Novel Targeted Therapies Will Drive Growth In The Acute Leukemia Markets Beginning In 2015
4. The Leukemia & Lymphoma Society and Avella Specialty Pharmacy to Present Free Event on Oral Chemotherapy Drugs
5. Ambit and Astellas Announce Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the 54th Annual Meeting of the American Society of Hematology
6. Burlington Coat Factory Completes Another Record Year of Supporting The Leukemia & Lymphoma Society in its Quest to Beat Cancer
7. Ambit Biosciences Completes $50 Million Financing to Advance Lead Drug Candidate in Acute Myeloid Leukemia
8. Constellation Pharmaceuticals and The Leukemia & Lymphoma Society Partner to Develop Novel BET Inhibitor for the Treatment of Hematologic Malignancies
9. Actinium Pharmaceuticals Commences Screening for the Second Cohort of Patients in the Companys Ongoing Phase I/II Trial in Acute Myeloid Leukemia
10. Actinium Pharmaceuticals Announces The Addition of The Fred Hutchinson Cancer Research Center To Actiniums Multicenter Clinical Trial For Patients With Acute Myeloid Leukemia
11. Trovagene, Inc., Announces Issuance of U.S. Patent for NPM Mutants to Diagnose and Monitor Acute Myeloid Leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 2014 UBM Medica US announces that  ... to help oncologists and other clinicians gain a better ... of targeted therapies and immunotherapies, discusses some of the ... Every September, Blood Cancer Awareness Month ... about blood cancers—helping to increase survival rates and improve ...
(Date:9/19/2014)... 19, 2014  Pressure BioSciences, Inc. (OTCQB: PBIO) ... received and approved all parts required to build ... begun to manufacture the new PCT-based instrument system.  ... ready for shipment by mid-October and that additional ... a rate of about one per week thereafter.  ...
(Date:9/19/2014)... , Sept. 19, 2014  Over 200 runners ... Future to Benefit the Radiation Oncology Institute (ROI), hosted ... at Golden Gate Park in San Francisco.  ... Moore , CEO of Radiation Business Solutions, "but ... have raised over $70,000 for the ROI this year. ...
Breaking Medicine Technology:OncoTherapy Network Highlights National Blood Cancer Awareness Month 2OncoTherapy Network Highlights National Blood Cancer Awareness Month 3OncoTherapy Network Highlights National Blood Cancer Awareness Month 4Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 2Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 3Fifth Annual 5K Run for the Future to Benefit the Radiation Oncology Institute Breaks Attendance, Donation Records 2Fifth Annual 5K Run for the Future to Benefit the Radiation Oncology Institute Breaks Attendance, Donation Records 3
... CHADDS FORD, Pa., Oct. 22 Endo Pharmaceuticals (Nasdaq: ... and Company 21st Annual Healthcare Conference on Tuesday, November 2, 2010, ... Endo, will review the company,s products and development programs. ... from Endo,s website at www.endo.com under the investors section. ...
... Pharmaxis (ASX: PXS) today announced significant results of pooled ... III trials of Bronchitol (inhaled mannitol) in people with ... presented for the first time at the North American ... addition, more results from the second trial (CF302) have ...
Cached Medicine Technology:Pharmaxis Announces Positive Combined Phase 3 Cystic Fibrosis Trial Results 2Pharmaxis Announces Positive Combined Phase 3 Cystic Fibrosis Trial Results 3Pharmaxis Announces Positive Combined Phase 3 Cystic Fibrosis Trial Results 4Pharmaxis Announces Positive Combined Phase 3 Cystic Fibrosis Trial Results 5
(Date:9/21/2014)... AstraZeneca’s Pulmicort is an ICS ... is used prophylactically for the maintenance treatment of ... budesonide, is an anti-inflammatory corticosteroid with a high ... includes the Pulmicort Flexhaler (budesonide) for adults and ... Pulmicort Respules for children between one and eight ...
(Date:9/21/2014)... than a quarter of house fires are started by ... ways. The first type of dryer fire occurs when the ... dryer fire occurs when lint builds up in the dryer vent ... malfunctioning electrical systems so if it doesn’t appear to be working ... some ways that you can prevent dryer fires. , Clean the ...
(Date:9/21/2014)... Burnaby Physiotherapists at Absolute PhysioCare & Sports ... to help them with preventative care. This is part ... will help clients understand their problem in a better ... in the healing process. With higher knowledge of their ... to facilitate the therapy that is initiated by the ...
(Date:9/21/2014)... New York (PRWEB) September 21, 2014 ... of their Risk Management Portal designed for Diocesan ... with the intent to support effective risk management ... scheduled to go live coinciding with Waldorf’s exhibition ... 21-24, 2014. , These applications were developed in ...
(Date:9/21/2014)... 2014 The asthma market saw ... it has become saturated with relatively efficacious standard ... (ICSs), inhaled corticosteroids and long-acting beta-agonists (ICS/LABAs), and ... generic competition. However, the launch of seven novel ... therapies delivered by the next-generation inhalers will strongly ...
Breaking Medicine News(10 mins):Health News:Pulmicort Asthma Market (Epidemiology, Etiology, Symptoms, Diagnosis, Pathology) Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 2Health News:Pulmicort Asthma Market (Epidemiology, Etiology, Symptoms, Diagnosis, Pathology) Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 3Health News:Pulmicort Asthma Market (Epidemiology, Etiology, Symptoms, Diagnosis, Pathology) Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 4Health News:Restoration Local Offers Tips to Avoid Dryer Fires 2Health News:Restoration Local Offers Tips to Avoid Dryer Fires 3Health News:Burnaby Physiotherapists Now Provide Educational Information for Preventative Care 2Health News:Waldorf Risk Solutions Releases New Risk Management Portal 2Health News:Spiriva Asthma Market (Tiotropium Bromide) Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 2Health News:Spiriva Asthma Market (Tiotropium Bromide) Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 3Health News:Spiriva Asthma Market (Tiotropium Bromide) Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 4
... 7-9 in Las Vegas , ... Denver -- As part of its ... Water Works Association (AWWA), the authoritative resource on safe water, today ... , Oct. 7-9, 2009, in Las Vegas., , , , ,Debuted last ...
... comes as use of stimulant for enhanced mental function is ... -- A drug used to treat narcolepsy is increasingly being ... evidence that it also harbors the potential for abuse. , ... brain, the new study shows. , "This drug does seem ...
... Carestream Health, Inc. is a leading provider of dental and medical ... ... NY (PRWEB) March 17, 2009 -- Carestream Health, Inc., announced new ... (DR) imaging systems that provide direct digital capture of medical x-ray ...
... The Netherlands A number of updated guidelines will be ... of Urology (EAU) held in Stockholm, from 17 though 21 ... based on the extended text documents will also be available ... of clinical guidelines is one of the core activities of ...
... Ill., March 17 It happens in an instant, standing ... Vice President Joe Biden,s mother. For 92 year old ... guarding against taking a tumble is fast becoming a full ... now take added precautions to help prevent a fall and ...
... tobacco, and drug useOLYMPIA, Wash., March 17 A ... good choices about their health. Still, far too many ... behavior.The Healthy Youth Survey focuses on health risk behaviors. ... by more than 210,000 public school kids around the ...
Cached Medicine News:Health News:AWWA partners with WaterSmart Innovations conference 2Health News:Narcolepsy Drug Might Be Addictive 2Health News:Narcolepsy Drug Might Be Addictive 3Health News:Carestream Health Announces New Orders From from U.S. Healthcare Facilities For for Its Digital Radiography Solutions 2Health News:EAU launches new clinical guidelines for 2009 -- kidney cancer 2Health News:Safety Alert: From the American Academy of Orthopaedic Surgeons 2Health News:New Survey Results Give a Window Into Teen Behavior and Risks 2Health News:New Survey Results Give a Window Into Teen Behavior and Risks 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: